BRAF-Mutant Papillary Thyroid Cancer

1. Disease Information

1.1 Overview / definition

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer subtype and a malignancy of thyroid follicular epithelial cells. “BRAF‑mutant PTC” refers to PTC harboring activating BRAF alterations, most commonly BRAFV600E, a driver that constitutively activates MAPK signaling. BRAFV600E is defined as c.1799T>A (p.Val600Glu). (webster2024theprevalenceand pages 2-2)

Abstract‑quotable definition (RAI‑refractory context): In radioiodine‑refractory disease, loss of differentiation features (including iodide uptake) is “correlat[ed] with the degree of mitogen‑activated protein kinase (MAPK) activation, which is higher in tumors with BRAF…mutations…Hence, inhibition of…MEK…could sensitize RAI refractivity.” (Aashiq et al., 2019; PMID not extracted by tool; DOI/URL in source) (tan2024tertpromotermutations pages 9-10)

1.2 Key identifiers and ontology mapping

Because this run’s tool outputs were optimized for literature/trials rather than ontology registries (OMIM/MeSH/ICD/MONDO direct lookups are not available as dedicated tools here), only partial identifiers can be provided: - Disease family identifiers present in Open Targets evidence: - Papillary thyroid carcinoma: Open Targets disease ID EFO_0000641 (tan2024tertpromotermutations pages 9-10) - Differentiated thyroid carcinoma: Open Targets disease ID EFO_1002017 (tan2024tertpromotermutations pages 9-10) - Gene/target: BRAF (Ensembl: ENSG00000157764) (tan2024tertpromotermutations pages 9-10)

1.3 Synonyms / alternative names

• Papillary thyroid cancer
• Papillary thyroid carcinoma
• Differentiated thyroid carcinoma (broader category)
• BRAFV600E‑positive PTC
• “BRAF‑like” PTC (molecular class used in TCGA‑style frameworks) (abdelmoula2024reviewhistopathologicalmolecularclassifications pages 5-5)

1.4 Data provenance

The information here is derived primarily from aggregated disease‑level resources (peer‑reviewed reviews, retrospective cohorts, meta‑analyses, and ClinicalTrials.gov records), rather than individual EHR records. (brumfield2025prevalenceandclinical pages 1-2, ovcaricek2024redifferentiationtherapiesin pages 6-7, NCT01534897 chunk 1)

2. Etiology

2.1 Disease causal factors

Primary causal factor (somatic driver): The dominant causal event in BRAF‑mutant PTC is a somatic activating mutation in BRAF, especially BRAFV600E, which drives high‑output MAPK/ERK signaling. (webster2024theprevalenceand pages 2-2, cortas2023tyrosinekinaseinhibitors pages 2-4)

2.2 Risk factors

Molecular risk factors for aggressive behavior / dedifferentiation - TERT promoter (TERTp) mutations are repeatedly highlighted as strong adverse prognostic markers in DTC and interact negatively with BRAFV600E. (tan2024tertpromotermutations pages 9-10)

Population/clinical risk factors for recurrence (example cohort): In a 301‑patient single‑institution cohort, recurrence was associated with large‑volume nodal disease burden and male sex, rather than BRAFV600E alone on multivariable analysis. (brumfield2025prevalenceandclinical pages 1-2)

2.3 Protective factors

Protective factors specific to BRAF‑mutant PTC were not clearly identified in the gathered evidence. However, the incidence‑trend literature argues that reductions in overdiagnosis/changes in screening and management practices can reduce observed incidence of thyroid cancer (including PTC), which can be viewed as a population‑level protective factor against overtreatment. (fwelo2024impactofamerican pages 1-2)

2.4 Gene–environment interactions

Explicit GxE interaction data were not captured in the retrieved evidence. One review notes BRAF fusions in radiation‑associated cases, indicating environmental exposure may shape mutation spectra in some settings, but quantitative interaction effects were not extractable from the provided excerpts. (voinea2024pathogenesisandmanagement pages 2-4)

3. Phenotypes (clinical presentation)

3.1 Core phenotypes and suggested HPO terms

PTC commonly presents as a thyroid nodule and may involve cervical lymphadenopathy; BRAFV600E has been associated in many meta‑analyses with adverse local features (extrathyroidal extension, nodal metastasis), though results vary by cohort and adjustment. (webster2024theprevalenceand pages 2-2, brumfield2025prevalenceandclinical pages 1-2)

Suggested phenotype mapping (HPO terms; canonical terms shown, not all were explicitly listed in the evidence excerpts): - Thyroid nodule / thyroid mass: Thyroid nodule (HP:0002890) - Cervical lymph node metastasis / lymphadenopathy: Lymphadenopathy (HP:0002716) - Extrathyroidal extension / local invasion: Invasive neoplasm (HP:0100758) (approximate mapping) - Multifocal tumors: Multifocal neoplasm (HP:0030445) (approximate mapping) - Distant metastasis (advanced cases): Metastatic neoplasm (HP:0003002)

3.2 Frequency and clinical correlations (selected recent quantitative data)

• BRAFV600E prevalence in PTC: A single‑institution series found 78.7% BRAFV600E prevalence overall, with enrichment by morphology (classic 88%, extensive follicular growth 38%, tall cell 100%). (Brumfield 2025; publication date Apr 2025; URL: https://doi.org/10.1007/s12022-025-09859-y) (brumfield2025prevalenceandclinical pages 1-2)
• Association with recurrence: In the same cohort, BRAFV600E was not significantly associated with recurrence (HR 0.71; p=0.4) after adjusting for clinicopathologic factors. (brumfield2025prevalenceandclinical pages 1-2)

3.3 Quality of life impact

Quality‑of‑life instruments (e.g., EQ‑5D, SF‑36, PROMIS) were not reported in the evidence excerpts retrieved here; for BRAF‑mutant disease, QoL is often dominated by treatment effects (thyroidectomy, lifelong levothyroxine, potential systemic therapy toxicity in RAIR disease), but quantitative QoL data were not extractable from these sources.

4. Genetic / Molecular Information

4.1 Causal genes

• BRAF (HGNC:1097; Ensembl ENSG00000157764 as returned via Open Targets) is the key causal/driver gene in this molecular subtype. (tan2024tertpromotermutations pages 9-10)

4.2 Pathogenic variants

• BRAFV600E (c.1799T>A; p.Val600Glu): activating missense hotspot variant and predominant BRAF alteration in PTC. (webster2024theprevalenceand pages 2-2)

Somatic vs germline: BRAFV600E in PTC is a somatic oncogenic driver in the vast majority of cases (not presented as germline in the retrieved excerpts). (webster2024theprevalenceand pages 2-2)

4.3 Modifier/cooperating alterations

• TERT promoter mutations: strongly adverse modifier, especially in combination with BRAFV600E. (tan2024tertpromotermutations pages 9-10)
• Additional cooperating alterations referenced in reviews (e.g., TP53, PTEN) are associated with aggressiveness and dedifferentiation, and are relevant to progression beyond well‑differentiated PTC. (abdelmoula2024reviewhistopathologicalmolecularclassifications pages 5-5)

4.4 Epigenetic/chromatin mechanisms

Chromatin remodeling state can determine whether MAPK blockade can restore thyroid differentiation. Loss of SWI/SNF complex subunits in BRAF‑driven mouse models produced a repressive chromatin state and resistance to redifferentiation. (tan2024tertpromotermutations pages 9-10)

4.5 Suggested GO and Cell Ontology (CL) terms

Key pathways/processes (GO Biological Process suggestions): - MAPK cascade (GO:0000165) - ERK1/ERK2 cascade (GO:0070371) - Regulation of cell proliferation (GO:0008283) - Epithelial cell differentiation (GO:0030855) - Iodide transport (GO:0015705)

Key cell types (CL suggestions): - Thyroid follicular cell / thyrocyte (CL:0000115) - Myeloid‑derived suppressor cell (not always in CL as a single canonical term; can map to immature myeloid populations; the study explicitly focuses on MDSCs) (tan2024tertpromotermutations pages 9-10)

5. Environmental Information

No specific toxins, lifestyle factors, or infectious agents were supported by the retrieved evidence snippets as causal contributors specifically to BRAF‑mutant PTC. In the incidence‑trend literature, imaging and screening practices are emphasized as drivers of apparent incidence, rather than an identified infectious etiology. (fwelo2024impactofamerican pages 1-2)

6. Mechanism / Pathophysiology

6.1 Causal chain (high‑level)

1. Somatic BRAFV600E activates the MAPK/ERK pathway with high signaling output. (webster2024theprevalenceand pages 2-2, cortas2023tyrosinekinaseinhibitors pages 2-4)
2. High MAPK output drives dedifferentiation (downregulation of thyroid lineage transcriptional programs) and disrupts the iodide‑handling machinery, including NIS/SLC5A5 expression and/or membrane targeting. (voinea2024pathogenesisandmanagement pages 2-4, chen2024systemictreatmentsfor pages 1-2)
3. Reduced NIS function causes loss of radioiodine avidity and contributes to radioiodine‑refractory (RAIR) disease, which has markedly worse outcomes. (cortas2023tyrosinekinaseinhibitors pages 1-2, chen2024systemictreatmentsfor pages 1-2)
4. Co‑mutations (e.g., TERT promoter) accelerate progression/dedifferentiation, increasing RAIR likelihood and worsening prognosis. (tan2024tertpromotermutations pages 9-10)

Abstract‑quotable mechanistic framing (RAIR‑DTC): “alterations…initiating tumour cell dedifferentiation events, accompanied by reduced or virtually absent expression of the sodium/iodine symporter (NIS)…[leading to] iodine‑refractory differentiated thyroid cancer (RAIR‑DTC)” (Zhao et al., Frontiers in Endocrinology 2024; URL: https://doi.org/10.3389/fendo.2023.1320044). (tan2024tertpromotermutations pages 9-10)

6.2 Immune microenvironment mechanism (expert mechanistic insight)

BRAFV600E can promote immune suppression via a TBX3–CXCR2 ligand axis that recruits myeloid‑derived suppressor cells (MDSCs); experimental inhibition of CXCR2 or repression of MDSCs improved the effect of MAPK inhibitor therapy in advanced thyroid cancer models. (Zhang et al., Nature Communications 2022; URL: https://doi.org/10.1038/s41467-022-29000-5). (tan2024tertpromotermutations pages 9-10)

7. Anatomical Structures Affected

7.1 Organ/tissue

• Primary organ: thyroid gland (UBERON:0002046)
• Primary tissue/cell compartment: follicular epithelium (thyrocytes) (CL:0000115)
• Common metastatic site (advanced disease): cervical lymph nodes (UBERON:0002509; approximate) (supported conceptually by clinical associations in reviews, though frequencies vary) (webster2024theprevalenceand pages 2-2)

7.2 Subcellular (GO Cellular Component suggestions)

• Plasma membrane localization of NIS is central to RAI uptake (GO:0005886 plasma membrane; in context of NIS trafficking/function). (voinea2024pathogenesisandmanagement pages 2-4)

8. Temporal Development

8.1 Onset

Typically adult onset (many cases diagnosed in middle age), with notable incidence in young adults; PTC is also common in pediatric/adolescent thyroid cancers but BRAFV600E is less frequent in children than adults. (branigan2023developmentofnovel pages 1-2, cortas2023tyrosinekinaseinhibitors pages 2-4)

8.2 Progression

Most DTC/PTC is indolent, but a subset progresses to metastatic and RAIR disease. Reviews cited in this run indicate that RAIR disease comprises 5–15% of DTCs and ~50% of metastatic DTCs, reflecting progression/dedifferentiation in advanced settings. (chen2024systemictreatmentsfor pages 1-2)

9. Inheritance and Population

9.1 Epidemiology and trends

SEER‑based U.S. incidence trends (2000–2020) and guideline inflection points: A joinpoint analysis of SEER data found thyroid cancer incidence increased rapidly from 2000–2009 (AAPC 5.8%), increased modestly 2010–2015 (AAPC 1.1%), then decreased significantly 2016–2020 (AAPC −4.8%), with inflection points around 2009 and 2015 aligned to ATA management revisions. (Fwelo et al., Journal of Clinical Medicine, Dec 2024; URL: https://doi.org/10.3390/jcm14010028). (fwelo2024impactofamerican pages 1-2)

Histology‑specific trends: In the same study’s stratified results, papillary thyroid carcinoma showed the largest increase over 2000–2020 (overall APC 3.3) while follicular thyroid carcinoma declined modestly. (fwelo2024impactofamerican pages 7-8)

9.2 BRAF mutation prevalence in PTC

A 2025 single‑institution cohort reported 78.7% BRAFV600E prevalence, with strong subtype enrichment (classic PTC 88%; tall cell 100%). (brumfield2025prevalenceandclinical pages 1-2)

9.3 Inheritance

BRAFV600E in PTC is primarily somatic; Mendelian inheritance is not applicable for the disease entity as defined here. (webster2024theprevalenceand pages 2-2)

10. Diagnostics

10.1 Pathology and molecular testing

Actionable biomarker testing (expert consensus): A 2024 expert panel consensus statement emphasizes that identification of actionable biomarkers via germline and somatic testing is now integral to thyroid cancer management, and notes that RET and BRAF testing are well established. (Mete et al., Endocrine Pathology, Nov 2024; URL: https://doi.org/10.1007/s12022-024-09836-x). (tan2024tertpromotermutations pages 9-10)

BRAFV600E detection: The Brumfield cohort notes VE1 immunohistochemistry is used clinically and described as highly sensitive/specific in that context. (brumfield2025prevalenceandclinical pages 1-2)

10.2 Imaging / RAIR evaluation

RAIR‑DTC is characterized by absent or lost radioiodine uptake; reviews describe a diagnostic shift to alternative imaging (e.g., FDG PET/CT in RAIR contexts) and exploration of additional tracers, though specific performance statistics were not extractable from the cited excerpts. (tan2024tertpromotermutations pages 9-10)

11. Outcome / Prognosis

11.1 Prognostic biomarkers and statistics

TERT promoter as major adverse prognostic marker and BRAFV600E synergy: - In a 243‑patient DTC NGS cohort, among those with TERTp mutations, 80% (20/25) had RAIR‑DTC; RAIR‑DTC was 6.3% (9/143) in BRAFV600E‑only vs 82.4% (14/17) in BRAFV600E+TERTp. (Tan et al., Scientific Reports, Oct 2024; URL: https://doi.org/10.1038/s41598-024-75087-9). (tan2024tertpromotermutations pages 9-10)

Stage‑system integration (expert analysis): BRAFV600E alone did not correlate strongly with ATA/TNM staging and did not significantly predict persistent disease in one 296‑patient study, whereas TERTp (alone or with BRAFV600E) correlated with higher ATA/TNM stages and predicted persistent disease. (Mukhtar et al., Frontiers in Endocrinology, Oct 2023; URL: https://doi.org/10.3389/fendo.2023.1270796). (tan2024tertpromotermutations pages 9-10)

RAIR prognosis: Reviews in this run summarize markedly poor outcomes once RAIR develops (e.g., 5‑year OS reported as ~10% in one review excerpt; additional reviews report very poor long‑term survival). (cortas2023tyrosinekinaseinhibitors pages 1-2, tan2024tertpromotermutations pages 9-10)

12. Treatment

12.1 Standard real‑world management in differentiated thyroid cancer

• Surgery (thyroidectomy with risk‑adapted lymph node management)
• Radioiodine (I‑131) for appropriately selected cases
• TSH suppression with levothyroxine as standard adjunctive management These are referenced as the standard backbone in RAIR‑DTC reviews as the pre‑RAIR state; specific surgical outcome statistics were not extractable from the evidence snippets in this run. (chen2024systemictreatmentsfor pages 1-2)

MAXO suggestions: - Thyroidectomy (MAXO term suggestion: thyroidectomy) - Radioiodine therapy (MAXO suggestion: radioiodine therapy) - Thyroid hormone suppression therapy (MAXO suggestion: hormone therapy)

12.2 Systemic therapy for RAIR‑DTC (standards and targeted options)

Multiple contemporary reviews agree that for RAIR differentiated thyroid cancer: - Lenvatinib and sorafenib are standard first‑line multitargeted TKIs. - Cabozantinib is a standard second‑line option after progression on prior TKI therapy. (Chen et al., Frontiers in Endocrinology 2024; URL: https://doi.org/10.3389/fendo.2024.1346476) (chen2024systemictreatmentsfor pages 1-2)

A 2023 review similarly states: “Currently, Lenvatinib and Sorafenib…represent the standard first‑line systemic treatment options…while Cabozantinib is the standard second‑line treatment option.” (Cortas & Charalambous, Life 2023; URL: https://doi.org/10.3390/life14010022) (cortas2023tyrosinekinaseinhibitors pages 1-2)

12.3 BRAF‑directed therapy and outcomes in BRAF‑mutant RAIR‑DTC

Anti‑proliferative targeted therapy (not redifferentiation‑specific): - Vemurafenib in BRAF‑mutant RAIR‑DTC showed objective responses in a phase II experience summarized in a 2023 review: ORR 38.5% (treatment‑naïve) and 27.3% (previous VEGFR inhibitor), with toxicity including grade 3–4 AEs (65%) and secondary skin squamous cell carcinoma (27%). (cortas2023tyrosinekinaseinhibitors pages 10-12) - A randomized phase II comparison of dabrafenib vs dabrafenib+trametinib reported ORRs in the ~30–48% range depending on response criteria (modified‑RECIST vs RECIST 1.1). (cortas2023tyrosinekinaseinhibitors pages 10-12)

12.4 Redifferentiation therapy (MAPK pathway inhibition to restore RAI uptake)

Key concept: Short‑course MAPK pathway inhibition (BRAF±MEK inhibition) can restore NIS function/iodide uptake in some BRAFV600E‑mutant RAIR tumors, enabling “salvage” I‑131 therapy. (cortas2023tyrosinekinaseinhibitors pages 14-15, ovcaricek2024redifferentiationtherapiesin pages 6-7)

Recent/redifferentiation outcomes highlighted in 2024 review: - In a phase II BRAF‑mutant cohort (MERAIODE approach with dabrafenib + trametinib), post‑therapy uptake occurred in 20/21 evaluable patients; at 6 months: PR 38% (8/21), SD 52% (11/21), PD 10% (2/21); PFS 82% at 1 year and 68% at 2 years. (Ovčariček et al., J Clin Med, Nov 2024; URL: https://doi.org/10.3390/jcm13237021) (ovcaricek2024redifferentiationtherapiesin pages 6-7)

Real‑world implementation caution: A Mayo Clinic retrospective series of 33 RAIR‑DTC patients receiving genotype‑guided inhibitors reported restored RAI uptake in 57.6% overall, but only 38.9% (7/18) of BRAF‑mutant tumors redifferentiated versus 100% (11/11) RAS‑mutant tumors, suggesting BRAF‑mutant follicular‑lineage context and/or deeper dedifferentiation may limit redifferentiation success. (Toro‑Tobon et al., Thyroid, Jan 2024; URL: https://doi.org/10.1089/thy.2023.0456) (jesus2023addonradioiodineduring pages 1-3)

12.5 Ongoing and completed clinical trials (ClinicalTrials.gov)

Selected BRAF‑mutant PTC/DTC trials retrieved in this run: - NCT01534897 (completed; results posted 2017‑03‑15): Dabrafenib (GSK2118436) redifferentiation strategy in radioiodine‑refractory BRAF V600E PTC; primary outcome = number of patients with increased RAI uptake after ~25 days of dabrafenib; designed to deliver therapeutic I‑131 if uptake restored. (ClinicalTrials.gov; https://clinicaltrials.gov/study/NCT01534897) (NCT01534897 chunk 1) - NCT01286753 (completed): Vemurafenib in metastatic/unresectable BRAF V600 mutation PTC; clinical publication cited in the record (Brose et al., Lancet Oncology 2016). (https://clinicaltrials.gov/study/NCT01286753) (NCT01286753 chunk 2) - NCT04061980 (active/pending in review excerpt): Encorafenib + binimetinib ± nivolumab in metastatic RAIR BRAF V600 mutant thyroid cancer; phase 2 with ORR primary endpoint. (https://clinicaltrials.gov/study/NCT04061980) (cortas2023tyrosinekinaseinhibitors pages 19-20) - NCT06440850 (recruiting; start 2024‑07‑15): Vemurafenib + cobimetinib as a redifferentiation strategy before initial RAI in high‑risk BRAFV600E‑mutant DTC; primary outcome uses ATA response categories. (https://clinicaltrials.gov/study/NCT06440850) (NCT06440850 chunk 1)

13. Prevention

No disease‑specific primary prevention strategies exist for sporadic BRAFV600E‑mutant PTC. However, overdiagnosis mitigation (risk‑adapted ultrasound/FNA, refined biopsy criteria, and guideline‑driven management) is supported as a public‑health strategy to reduce unnecessary diagnosis/treatment burden. SEER trend inflection points aligned with ATA revisions support this interpretation. (fwelo2024impactofamerican pages 1-2, fwelo2024impactofamerican pages 2-4)

14. Other Species / Natural Disease

Natural companion‑animal disease analogs were not retrieved in the evidence excerpts. This report focuses on mechanistic translation using experimental models (see below).

15. Model Organisms / Model Systems

15.1 Mouse models

Authoritative review evidence indicates genetically engineered mouse models (GEMMs) with thyroid‑specific BRAFV600E expression closely phenocopy human PTC histology; in mice, Braf‑driven initiation depends on TSH receptor signaling, and MAPK inhibition can restore differentiation and radioiodine avidity. (Fagin et al., Nat Rev Cancer 2023; URL: https://doi.org/10.1038/s41568-023-00598-y) (fagin2023pathogenesisofcancers pages 24-25)

15.2 Murine BRAFV600E PTC cell lines from GEMMs (2023 development)

A 2023 study generated six novel murine BRAFV600E‑driven PTC cell lines derived from a BrafV600E+/−/Pten+/−/TPO‑Cre model; the lines span varied developmental stages/sexes and show differing differentiation and invasive potential, enabling preclinical therapeutic evaluation and transplantation into immunocompetent hosts. (Branigan et al., Cancers, Jan 2023; URL: https://doi.org/10.3390/cancers15030879) (branigan2023developmentofnovel pages 1-2)

15.3 Organoids

A 2024 Oncogene paper created thyroid organoids with inducible murine BrafV637E (human‑equivalent of BRAF V600E), reporting that Braf activation triggers MAPK activation and dedifferentiation, and that combining MAPK and PI3K inhibitors reversed dedifferentiation and restored follicle organization/function in vitro. (Lasolle et al., Oncogene, Nov 2024; URL: https://doi.org/10.1038/s41388-023-02889-y). (tan2024tertpromotermutations pages 9-10)

15.4 Engineered embryonic stem cell thyroid cancer systems

A Nature Communications 2023 study engineered thyroid progenitor cells with BRAF V600E (or NRAS Q61R) using CRISPR‑Cas9 to generate thyroid cancer histotypes in vitro/in vivo; BRAF V600E in thyroid progenitors generated papillary thyroid carcinoma‑like tumors, supporting a progenitor‑state susceptibility concept. (Veschi et al., Nat Commun, Mar 2023; URL: https://doi.org/10.1038/s41467-023-36922-1). (tan2024tertpromotermutations pages 9-10)

Summary evidence map

Table: This table summarizes the main molecular mechanisms and clinically relevant associations in BRAF-mutant papillary thyroid carcinoma, including dedifferentiation, radioiodine refractoriness, prognostic modifiers, and resistance biology. It is useful as a compact evidence map for knowledge-base curation and clinical interpretation.

Notes on evidence gaps

• Direct ontology identifiers (MeSH tree number, ICD‑10/ICD‑11 codes, Orphanet/OMIM entries) and disease‑specific MONDO IDs were not retrievable with the available tools in this run; the closest structured disease IDs obtained were Open Targets EFO IDs for papillary thyroid carcinoma and differentiated thyroid carcinoma. (tan2024tertpromotermutations pages 9-10)
• Detailed symptom frequencies, formal diagnostic criteria, and QoL metrics were not present in the excerpts captured; these typically require guideline PDFs or dedicated clinical cohorts focused on presentation/QoL.

References

1. (webster2024theprevalenceand pages 2-2): Alyssa Webster, Rami M. Elshazli, Dylan Pinion, Robert D. E. Clark, Grace Kelly, Peter P. Issa, Mohammad H. Hussein, Manal S. Fawzy, Eman A. Toraih, and Emad Kandil. The prevalence and prognostic implications of brafk601e mutations in thyroid neoplasms: a systematic review and meta‐analysis. Head & Neck, 46:3133-3145, Oct 2024. URL: https://doi.org/10.1002/hed.27950, doi:10.1002/hed.27950. This article has 2 citations.

2. (tan2024tertpromotermutations pages 9-10): Gongxun Tan, Bingquan Jin, Xiaoqin Qian, Yuguo Wang, Guoliang Zhang, Enock Adjei Agyekum, Feng Wang, Liang Shi, Yue Zhang, Zhenwei Mao, Chunhe Shi, Ying Xu, Xiuying Li, Lele Zhang, and Shaohua Li. Tert promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-75087-9, doi:10.1038/s41598-024-75087-9. This article has 13 citations and is from a peer-reviewed journal.

3. (abdelmoula2024reviewhistopathologicalmolecularclassifications pages 5-5): NB Abdelmoula and B Abdelmoula. Review histopathological-molecular classifications of papillary thyroid cancers: challenges in genetic practice settings. Unknown journal, 2024.

4. (brumfield2025prevalenceandclinical pages 1-2): Alexandria Brumfield, Sara Abou Azar, Rachel Nordgren, Ronald N. Cohen, David Sarne, Xavier M. Keutgen, Megan Applewhite, Peter Angelos, and Nicole A. Cipriani. Prevalence and clinical impact of braf p.v600e mutation in papillary thyroid carcinoma. Endocrine Pathology, Apr 2025. URL: https://doi.org/10.1007/s12022-025-09859-y, doi:10.1007/s12022-025-09859-y. This article has 10 citations and is from a peer-reviewed journal.

5. (ovcaricek2024redifferentiationtherapiesin pages 6-7): Petra Petranović Ovčariček, Murat Tuncel, Atena Aghaee, Alfredo Campennì, and Luca Giovanella. Redifferentiation therapies in thyroid oncology: molecular and clinical aspects. Journal of Clinical Medicine, 13:7021, Nov 2024. URL: https://doi.org/10.3390/jcm13237021, doi:10.3390/jcm13237021. This article has 8 citations.

6. (NCT01534897 chunk 1): Lori J. Wirth, MD. Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436. Massachusetts General Hospital. 2012. ClinicalTrials.gov Identifier: NCT01534897

7. (cortas2023tyrosinekinaseinhibitors pages 2-4): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

8. (fwelo2024impactofamerican pages 1-2): Pierre Fwelo, Natalia I. Heredia, Ruosha Li, Ayrton Bangolo, Vignesh K. Nagesh, Simcha Weissman, and Xianglin L. Du. Impact of american thyroid association’s revised cancer management guidelines on thyroid cancer incidence trends: a retrospective cohort study, 2000–2020. Journal of Clinical Medicine, 14:28, Dec 2024. URL: https://doi.org/10.3390/jcm14010028, doi:10.3390/jcm14010028. This article has 2 citations.

9. (voinea2024pathogenesisandmanagement pages 2-4): IA Voinea, E Petrova, N Dumitru, and A Cocoloș. Pathogenesis and management strategies in radioiodine-refractory differentiated thyroid cancer: from molecular mechanisms toward therapeutic approaches …. Unknown journal, 2024.

10. (chen2024systemictreatmentsfor pages 1-2): Piaohong Chen, Yu Yao, Huiwen Tan, and Jianwei Li. Systemic treatments for radioiodine-refractory thyroid cancers. Frontiers in Endocrinology, Oct 2024. URL: https://doi.org/10.3389/fendo.2024.1346476, doi:10.3389/fendo.2024.1346476. This article has 15 citations.

11. (cortas2023tyrosinekinaseinhibitors pages 1-2): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

12. (branigan2023developmentofnovel pages 1-2): Grace Purvis Branigan, Victoria Casado-Medrano, Alison B. O’Neill, Julio C. Ricarte-Filho, Nicole Massoll, Madeleine Salwen, Zachary Spangler, Michele Scheerer, Edward K. Williamson, Andrew J. Bauer, and Aime T. Franco. Development of novel murine brafv600e-driven papillary thyroid cancer cell lines for modeling of disease progression and preclinical evaluation of therapeutics. Cancers, 15:879, Jan 2023. URL: https://doi.org/10.3390/cancers15030879, doi:10.3390/cancers15030879. This article has 3 citations.

13. (fwelo2024impactofamerican pages 7-8): Pierre Fwelo, Natalia I. Heredia, Ruosha Li, Ayrton Bangolo, Vignesh K. Nagesh, Simcha Weissman, and Xianglin L. Du. Impact of american thyroid association’s revised cancer management guidelines on thyroid cancer incidence trends: a retrospective cohort study, 2000–2020. Journal of Clinical Medicine, 14:28, Dec 2024. URL: https://doi.org/10.3390/jcm14010028, doi:10.3390/jcm14010028. This article has 2 citations.

14. (cortas2023tyrosinekinaseinhibitors pages 10-12): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

15. (cortas2023tyrosinekinaseinhibitors pages 14-15): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

16. (jesus2023addonradioiodineduring pages 1-3): Filipe Miguel Montes de Jesus, Vittoria Espeli, Gaetano Paone, and Luca Giovanella. Add-on radioiodine during long-term braf/mek inhibition in patients with rai-refractory thyroid cancers: a reasonable option? Endocrine, 81:450-454, May 2023. URL: https://doi.org/10.1007/s12020-023-03388-6, doi:10.1007/s12020-023-03388-6. This article has 6 citations and is from a peer-reviewed journal.

17. (NCT01286753 chunk 2): A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation. Hoffmann-La Roche. 2011. ClinicalTrials.gov Identifier: NCT01286753

18. (cortas2023tyrosinekinaseinhibitors pages 19-20): Christos Cortas and Haris Charalambous. Tyrosine kinase inhibitors for radioactive iodine refractory differentiated thyroid cancer. Life, 14:22, Dec 2023. URL: https://doi.org/10.3390/life14010022, doi:10.3390/life14010022. This article has 13 citations.

19. (NCT06440850 chunk 1): Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation. City of Hope Medical Center. 2024. ClinicalTrials.gov Identifier: NCT06440850

20. (fwelo2024impactofamerican pages 2-4): Pierre Fwelo, Natalia I. Heredia, Ruosha Li, Ayrton Bangolo, Vignesh K. Nagesh, Simcha Weissman, and Xianglin L. Du. Impact of american thyroid association’s revised cancer management guidelines on thyroid cancer incidence trends: a retrospective cohort study, 2000–2020. Journal of Clinical Medicine, 14:28, Dec 2024. URL: https://doi.org/10.3390/jcm14010028, doi:10.3390/jcm14010028. This article has 2 citations.

21. (fagin2023pathogenesisofcancers pages 24-25): James A. Fagin, Gnana P. Krishnamoorthy, and Iñigo Landa. Pathogenesis of cancers derived from thyroid follicular cells. Nature Reviews Cancer, 23:631-650, Jul 2023. URL: https://doi.org/10.1038/s41568-023-00598-y, doi:10.1038/s41568-023-00598-y. This article has 77 citations and is from a domain leading peer-reviewed journal.

22. (yu2023molecularbasisand pages 5-6): Qiuxiao Yu, Xuwen Zhang, Li Li, Chi-zhi Zhang, Jian Huang, and Wenting Huang. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer. Asia‐Pacific Journal of Clinical Oncology, 19:279-289, Aug 2023. URL: https://doi.org/10.1111/ajco.13836, doi:10.1111/ajco.13836. This article has 16 citations.

1. Disease Information

Overview

BRAF-mutant papillary thyroid cancer is a molecular subtype of papillary thyroid carcinoma (PTC) defined by the presence of activating mutations in the BRAF serine/threonine kinase gene, most commonly the V600E hotspot mutation. PTC itself accounts for 85–90% of all thyroid malignancies, making it the most common endocrine cancer worldwide (PMID: 40980146). The BRAF V600E mutation occurs as a somatic (acquired) event in thyroid follicular cells and results in constitutive activation of the MAPK signaling pathway independent of upstream receptor tyrosine kinase stimulation.

Key Identifiers

Synonyms and Alternative Names

• BRAF V600E-positive papillary thyroid carcinoma
• BRAF-like PTC (TCGA molecular classification)
• BRAF-mutated differentiated thyroid cancer (DTC)
• Papillary thyroid cancer, classic variant (most commonly BRAF V600E-driven)
• PTC with BRAF V600E mutation

Information Sources

This characterization integrates aggregated disease-level resources (TCGA, COSMIC, GBD, SEER) with findings from individual patient cohorts, clinical trials, meta-analyses, and single-cell transcriptomic studies. The evidence base spans human clinical data, model organism studies, in vitro experiments, and computational analyses.

2. Etiology

Disease Causal Factors

The primary causal event in BRAF-mutant PTC is the somatic acquisition of the BRAF V600E mutation (chr7:140453136 A>T, GRCh37) in thyroid follicular epithelial cells. This missense mutation substitutes valine with glutamic acid at position 600 in the activation segment of the BRAF kinase domain, mimicking phosphorylation and locking the kinase in a constitutively active conformation. This results in continuous signaling through the RAS-RAF-MEK-ERK pathway, driving uncontrolled cell proliferation and survival (PMID: 39961465).

The BRAF V600E mutation is classified as a Class I BRAF mutation—a point mutation that activates BRAF as a monomer, independent of RAS signaling or dimerization (PMID: 39961465). This distinguishes it from Class II (in-frame insertions/deletions) and Class III (gene fusions) BRAF alterations.

Risk Factors

Genetic Risk Factors:

• BRAF V600E somatic mutation: The defining oncogenic driver, present in 40–80% of PTC across studies. A 2025 single-institution study found 78.7% of 301 PTC patients harbored BRAF V600E (PMID: 40237893). Among TCGA PTC samples, 48.4% (240/496) had BRAF mutations, with V600E comprising 97.9% (235/240).
• GWAS susceptibility loci: Multiple genome-wide association studies have identified DTC risk loci that may modify BRAF-mutant PTC susceptibility:
• 9q22.33 (FOXE1): rs965513, OR=1.7 per A allele (95% CI 1.2–2.3) (PMID: 25879635)
• 14q13.3 (NKX2-1): rs944289, OR=1.6 per A allele (95% CI 1.2–2.1) (PMID: 25879635)
• 2q35 (DIRC3): Confirmed across multiple populations (PMID: 23894154)
• 8p12 (NRG1): rs6996585, P=1.08×10⁻⁸ in Korean GWAS (PMID: 28703219)
• BATF and DHX35: rs10136427 (OR=1.30) and rs7267944 (OR=1.32) in Italian populations (PMID: 25029422)
• TERT promoter co-mutation: Synergistically worsens prognosis (see Section 4)

Environmental Risk Factors:

• Ionizing radiation exposure: The most well-established environmental risk factor for DTC. A study of indigenous populations near the former Semipalatinsk Nuclear Test Site found BRAF V600E exclusively in papillary carcinoma samples among radiation-exposed individuals (PMID: 41370693).
• Iodine intake: Dose-response meta-analysis of 25 studies (54,621 participants) revealed a U-shaped nonlinear relationship between urinary iodine concentration and thyroid nodule risk (P for nonlinearity <0.001), with increased risks at both deficient and excessive iodine levels (PMID: 41675569).
• Volcanic area residence: Exposure to volcanic emissions (gas, ash, lava) contaminates food chains with toxic compounds (PMID: 30104523).
• Obesity/metabolic dysfunction: NAFLD (non-alcoholic fatty liver disease) is an independent risk factor for lymph node metastasis in PTC (OR=1.285, 95% CI 1.052–1.570) and is associated with higher incidence of BRAF V600E mutation (PMID: 36696026).
• Sex: Female predominance (2–4:1 female-to-male ratio), with women accounting for 67% of all thyroid cancer cases globally (PMID: 41726144).
• Age: Mean age at diagnosis 40–45 years for PTC (PMID: 23014067).

Protective Factors

• Adequate iodine intake: More-than-adequate iodine showed a trend toward lower thyroid nodule prevalence (PMID: 41675569).
• Iodine prophylaxis legislation: Adoption of iodine prophylaxis programs improved thyroid cancer epidemiological outcomes in subsequent generations (PMID: 41370693).

Gene–Environment Interactions

The shift in PTC oncogenic patterns over recent decades—from RET/PTC rearrangements to BRAF V600E dominance—suggests changing environmental exposures interact with genetic susceptibility. Radiation exposure correlates with RET/PTC rearrangements, while the increasing BRAF V600E prevalence may reflect different environmental carcinogens or detection biases (PMID: 23014067).

3. Phenotypes

Clinical Presentation

BRAF V600E-specific associations (PMID: 40237893): - Classic PTC morphology: 88% of classic subtype PTCs express BRAF V600E - Tall cell variant: 100% express BRAF V600E (most aggressive histological subtype) - Follicular variant: Only 38% express BRAF V600E - Association with infiltrative borders, extrathyroidal extension, and intraglandular tumor spread (PMID: 26271724)

Quality of Life Impact

HRQOL meta-analysis of PTMC treatments found uncomplicated QALY weights ranging from 0.975 to 0.992, with no significant difference between active surveillance, thermal ablation, and surgery (P=.15) (PMID: 41452620). Patient treatment preferences are driven by aversion to treatment complications rather than to the treatments themselves (PMID: 41006152). Post-thyroidectomy patients report challenges in sensory function, body satisfaction, eating, speaking, and social interactions (PMID: 38384638). Thyroid cancer survivors report significant unmet informational, psychological, emotional, and practical support needs, often influenced by the "good cancer" label (PMID: 40402541).

4. Genetic/Molecular Information

Causal Gene: BRAF

Pathogenic Variants

BRAF V600E (c.1799T>A, p.Val600Glu): - Variant type: Missense (Class I BRAF mutation) - Somatic origin: Acquired in thyroid follicular cells; not inherited - Frequency in PTC: 40–80% across studies; TCGA: 48.4% (240/496 samples) - Functional consequence: Gain-of-function; constitutive kinase activation (~500-fold increased activity) - ACMG classification: Pathogenic (somatic oncogenic variant) - Population frequency: Extremely rare as germline variant in gnomAD; functionally exclusive to somatic tumors

Rare non-V600E BRAF variants in PTC (TCGA data): - K601E (n=1), N581_A598dup (n=1), K591_A598dup (n=1), P490_Q494del (n=1), T488_P492del (n=1) - Mutation types: 236 missense, 2 in-frame insertions, 2 in-frame deletions

Co-occurring Mutations and Modifier Genes

TERT promoter mutations (C228T, C250T): - Found in 38.2% of DTC patients harboring BRAF V600E (PMID: 40988283) - Coexisting BRAF V600E + TERT independently elevates risk of loss of RAI avidity (OR=4.8, P=.009) and accelerates recurrence (PMID: 40988283) - TERT is an independent predictor of lateral lymph node metastasis (OR=2.272, 95% CI 1.078–4.786) (PMID: 40184730)

TP53 mutations: Observed in the ATC component during dedifferentiation from PTC; not typically found in well-differentiated PTC (PMID: 40887557)

Additional co-occurring alterations: DICER1 (7%), PTEN (6%), RET (4%) in multifocal PTC (PMID: 40235071)

Epigenetic Information

• Promoter methylation: BRAF V600E correlates with methylation of TIMP3, CDH13, RASSF1A, and RARB tumor suppressor genes (PMID: 31006665)
• miRNA dysregulation: miR-146b, miR-221/222, and miR-375 are upregulated in BRAF V600E PTC and associated with aggressive behavior (PMID: 41660935)
• NOX4-mediated epigenetic mechanism: NOX4-derived oxidative DNA damage impairs thyroid differentiation through epigenetic reprogramming in BRAF-mutated RAI-refractory cells (PMID: 41694580)
• Global hypomethylation: Associated with chromosomal instability in aggressive PTC (PMID: 41660935)

5. Environmental Information

Environmental Factors

• Ionizing radiation: Most established risk factor; includes external radiation exposure, nuclear fallout, and therapeutic radiation (PMID: 41370693; PMID: 23132514)
• Volcanic emissions: Toxic compounds in gas, ash, and lava contaminate ground water and food chains (PMID: 30104523)
• Xenobiotic compounds: Environmental pollutants (PCBs, nitrates) accumulate and exert carcinogenic effects (PMID: 30104523)

Lifestyle Factors

• Obesity: BMI associated with altered clinicopathological features; MAFLD/NAFLD associated with higher BRAF V600E incidence and lymph node metastasis (PMID: 36696026; PMID: 38787506)
• Iodine intake: Both deficiency and excess modify thyroid cancer risk in a U-shaped relationship (PMID: 41675569)

Infectious Agents

Not directly applicable. No established infectious etiology for BRAF-mutant PTC, though chronic lymphocytic thyroiditis (Hashimoto's) shows complex immunological relationships with PTC (PMID: 38940753).

6. Mechanism / Pathophysiology

Molecular Pathways

Primary pathway — MAPK/ERK cascade:

BRAF V600E (constitutively active)
    |
    v
MEK1/2 phosphorylation (constitutive)
    |
    v
ERK1/2 phosphorylation (constitutive)
    |
    |---> Cell proliferation (Cyclin D1, c-Myc)
    |---> Survival (BCL-2 family)
    |---> NIS suppression --> RAI refractoriness
    |---> Dedifferentiation gene silencing
    |---> PD-L1 upregulation --> Immune evasion
    +---> Tumor invasion/migration (MMP, EMT)

The BRAF V600E mutation "activates the MAPK pathway and suppresses genes involved in iodine metabolism and differentiation" (PMID: 41368991). This constitutive signaling operates independently of extracellular growth factor stimulation.

Secondary pathway involvement: - PI3K/AKT/mTOR: Dysregulated in concert with MAPK; contributes to resistance (PMID: 39961465) - WNT/beta-Catenin: Beta-catenin attenuation inhibits tumor growth and promotes differentiation in BRAF-mutant models (PMID: 34224366) - NF-kB signaling: Drives organoid maturation; inhibition synergistically enhances therapeutic efficacy (PMID: 41761289)

Cellular Processes

• NIS suppression and RAI refractoriness: Up to 60% of PTC harbor BRAF V600E and may become RAI-refractory. NOX4-derived oxidative DNA damage impairs thyroid differentiation through an epigenetic mechanism, silencing NIS expression (PMID: 41694580). GO: GO:0006882 (cellular zinc ion homeostasis); GO:0055085 (transmembrane transport)
• Immune evasion: BRAF V600E positively correlates with PD-L1 and PD-1 expression in PTC tumor microenvironment (Type 1 PD-L1+/PD-1+ in 41% of cases), suggesting immune checkpoint therapies may be effective (PMID: 29651624)
• Dedifferentiation cascade: Progressive accumulation of TERT, TP53 mutations drives transition from PTC to PDTC to ATC, with LINE-1 retrotransposons and endogenous retroviruses reactivated during this process (PMID: 41462994; PMID: 41296188)
• Metabolic reprogramming: Fatty acid oxidation drives acetyl-CoA-dependent H3K9ac epigenetic reprogramming to promote adaptive resistance to BRAF-targeted therapy (PMID: 41862440)

Protein Dysfunction

BRAF V600E results in a constitutively active kinase domain (gain-of-function). The glutamic acid substitution at position 600 mimics the phosphorylated state of the activation segment, resulting in approximately 500-fold increased basal kinase activity. This removes the requirement for upstream RAS activation and RAF dimerization for signaling (PMID: 39577552).

Resistance Mechanisms

Three major resistance pathways to BRAF inhibitors have been identified:

1. TAZ/Hippo pathway: CRISPR screens identified TAZ (WWTR1) deficiency as synthetically lethal with BRAF inhibitor in ATC; TAZ loss triggers ferroptosis (PMID: 42035477)
2. Fatty acid oxidation (FAO): FAO drives acetyl-CoA-dependent H3K9ac epigenetic reprogramming mediating adaptive resistance (PMID: 41862440)
3. RAS pathway feedback activation: BRAF inhibitors induce feedback activation of RAS signaling in thyroid cancer cells (PMID: 34072194)

Molecular Profiling

Transcriptomics (TCGA): - BRAF-like vs. RAS-like molecular classification based on gene expression profiles - BRAF-like tumors characterized by MAPK pathway activation signature - Transcriptomic classifiers ("BRAF-like" and "RAS-like") more accurately predict iodine avidity, tumor aggressiveness, and treatment response than histology or genotype alone (PMID: 41685247)

Single-cell RNA sequencing: - scRNA-seq reveals "differentiation-dependent trajectory of tumor immune microenvironment remodeling—from immune activation/suppression coexistence in PTC, to immune exclusion in PDTC, and terminal exhaustion in ATC" (PMID: 41562080) - RGS5+ tumor subpopulation identified with prognostic significance; high prognostic immune score linked to genetic instability (PMID: 40132388) - Intra-tumoral heterogeneity in BRAF V600E PTC includes differentiation-dependent functional states (PMID: 41935217)

Proteomics: - Differential activation of MAPK and PI3K pathways critical for enhancing lateral lymph node metastatic potential (PMID: 39600146) - Patient-derived organoids (DEOs) achieve 92% driver gene concordance with parental tumors and faithfully recapitulate histopathological architecture and immune microenvironment (PMID: 41761289)

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

• Thyroid follicular epithelial cells (CL:0002258): Primary cell of origin for BRAF-mutant PTC
• Thyroid follicular tissue: Papillary architecture with fibrovascular cores, psammoma bodies
• Tumor microenvironment: CD3+, CD56+, CD68+, alpha-SMA+ cells recapitulated in patient-derived organoids (PMID: 41761289)

Subcellular Level

• Cytoplasm/cytosol (GO:0005829): BRAF kinase signaling
• Cell membrane (GO:0005886): NIS (SLC5A5) expression loss
• Nucleus (GO:0005634): ERK-mediated transcriptional changes
• Endoplasmic reticulum (GO:0005783): Unfolded protein response under BRAF inhibitor treatment (PMID: 42035477)

Localization

Thyroid nodules demonstrate right-side predominance (P=0.0004), and right-sided PTC with lymph node metastasis shows significantly more right-side-affected LNM (P=0.0007) (PMID: 40050757). The tumor can be unilateral or bilateral, unifocal or multifocal.

8. Temporal Development

Onset

• Typical age of onset: Adults aged 40–45 years for PTC (PMID: 23014067); median age 56 years for tall cell variant (PMID: 23682579)
• Pediatric PTC: BRAF V600E found in 50.8% of pediatric PTC (Chinese cohort, n=124); independently predicts non-excellent ATA outcomes (aOR=3.45, 95% CI 1.37–8.70) (PMID: 41499172; PMID: 39982551)
• Onset pattern: Insidious; typically discovered incidentally on imaging or as palpable thyroid nodule

Progression

AJCC 8th Edition Staging (age-dependent for DTC): - Stage I: Age <55 with any T, any N, M0; or age >=55 with T1-T2, N0, M0 - Stage II: Age <55 with any T, any N, M1; or age >=55 with T1-T2, N1, M0 or T3, N0-N1, M0 - Stage III-IV: Age >=55 with advanced T-stage, extensive nodal disease, or distant metastases

Disease course: Most patients (79.1%) present with early-stage disease. The 2022 WHO classification introduced "differentiated high-grade thyroid carcinoma" (DHGTC) as an intermediate entity between well-differentiated PTC and ATC (PMID: 36193717).

Dedifferentiation pathway (PMID: 41462994):

Well-differentiated PTC (BRAF V600E)
    | + TERT promoter mutation
    v
Poorly differentiated TC (PDTC)
    | + TP53 mutation
    v
Anaplastic thyroid carcinoma (ATC)

Recurrence patterns: Most recurrences occur within the first year (23.3%) or after 10 years post-thyroidectomy (35.7%). Patients with very early recurrences (<6 months) had TERT/BRAF V600E mutations in 69% of cases (PMID: 37336036).

9. Inheritance and Population

Epidemiology

• Global thyroid cancer incidence: Age-standardized incidence rate increased from 2.06 to 2.91 per 100,000 (1990–2021), EAPC=1.25 (PMID: 41726144)
• Global mortality: Modest decline (EAPC=-0.23), but DALYs remained high (14.57 million in 2021) (PMID: 41726144)
• Overdiagnosis: Estimated at approximately 25% globally; population-based study across 63 countries found 75.6% of 2.3 million thyroid cancer cases attributable to overdiagnosis (PMID: 39389067; PMID: 39330046)

Genetic Inheritance

BRAF V600E in PTC is a somatic mutation (not inherited). However: - Multifactorial/polygenic susceptibility: GWAS loci (FOXE1, NKX2-1, DIRC3, NRG1, BATF) confer inherited susceptibility to DTC - Familial non-medullary thyroid carcinoma: ~5% of PTC cases show familial clustering; modifier genes influence susceptibility - No Mendelian inheritance pattern for BRAF-mutant PTC specifically

Population Demographics

• Sex ratio: Female-to-male ~2.5–4:1; women account for 67% of cases globally (PMID: 41726144)
• Geographic variation: Highest incidence in South Korea, Cyprus, Ecuador, China, and Turkiye; high-SDI regions account for 72% of cases due to intensive screening, while low-SDI regions contribute 68% of deaths due to delayed diagnosis (PMID: 41726144; PMID: 39389067)
• BRAF V600E prevalence varies geographically: From 40% to >78% depending on population and study design

10. Diagnostics

Clinical Tests

Imaging: - Thyroid ultrasound (primary modality): ACR TI-RADS risk stratification system for thyroid nodules (PMID: 33112199) - CT neck with contrast: Optional for baseline AS assessment; evaluates extrathyroidal extension - I-123/I-131 whole-body scan: Assesses RAI avidity post-thyroidectomy - F-18-FDG PET/CT: For RAI-refractory disease and ATC

Laboratory tests: - Serum thyroglobulin (Tg): Primary tumor marker; ATA 2025 raised excellent-response threshold to 2.5 ng/mL (PMID: 41697551) - Anti-thyroglobulin antibodies (TgAb) - TSH, free T4

Biopsy: - Fine-needle aspiration biopsy (FNAB) with Bethesda System cytological classification - BRAF V600E immunohistochemistry (VE1 antibody): 88% concordance with NGS (PMID: 40614342)

Genetic/Molecular Testing

• BRAF V600E testing: Single-gene PCR, pyrosequencing, or allele-specific PCR from FNA or surgical specimens
• NGS panels: Myriapod panel (16 genes), Archer DX VariantPlex (31 genes) + FusionPlex (40 genes) achieve 100% sensitivity, 95.5% specificity (PMID: 41370117)
• 4-gene NGS panel (BRAF + 3 others): Cost-effective for predicting PTC in indeterminate cytology (PMID: 42083301)
• Liquid biopsy: ctDNA detection of BRAF V600E in plasma feasible; detected in 79.7% of malignant cases using 8-gene panel (PMID: 36744987)
• Transcriptomic classifiers: Thyroid GuidePx and similar tools classify tumors as "BRAF-like" vs "RAS-like" (PMID: 41685247)

Clinical Criteria

• ATA 2015 / ATA 2025 risk stratification: Low, intermediate, and high-risk categories based on clinicopathological features
• ATA 2025 update: Reclassified 89.1% of low-risk DTC as excellent response at baseline vs. 49.2% under ATA 2015 (P<0.001) (PMID: 41697551)

Differential Diagnosis

11. Outcome/Prognosis

Survival and Mortality

Prognostic Factors

Adverse prognostic factors: - BRAF V600E + TERT co-mutation (OR for RAI refractoriness = 4.8) - Age >=55 years with extrathyroidal extension (26.47-fold higher odds of incomplete response) (PMID: 41275349) - Tall cell variant histology (92.6% BRAF V600E positive; 36% present at stage III/IVA) (PMID: 23682579) - Hobnail variant (75% BRAF and p53 positivity) (PMID: 40560352) - Distant metastasis, incomplete resection, male sex, non-papillary histology

Favorable prognostic factors: - Young age at diagnosis (<55 years) - Classic PTC without high-grade features - Absence of TERT co-mutation - RAS-mutant or DICER1-mutant molecular profile (in pediatric PTC) (PMID: 41499172)

Prognostic Biomarkers

• BRAF V600E + TERT promoter co-mutation: Strongest molecular predictor of aggressive behavior
• Serum VEGFA: Elevated baseline independently associated with poor PFS (PMID: 31558473)
• RGS5+ tumor subpopulation: Outperforms existing models in predicting patient outcomes (PMID: 40132388)
• miR-146b, miR-221, miR-375: Promising predictors of aggressive disease progression (PMID: 41660935)

12. Treatment

Surgical Treatment (MAXO:0000136 — Thyroidectomy)

Radioactive Iodine Therapy (MAXO:0001298)

• Selective use recommended based on risk stratification
• RAI not significantly associated with DSS overall, but associated with >80% risk reduction in metastatic DTC (HR 0.192; CI 0.088–0.417) (PMID: 41817109)
• Decreasing utilization: adjuvant RAI rates fell from 48.7% to 19.3% after 2015 guidelines (PMID: 36326739)

Targeted Therapy (MAXO:0001525 — Targeted molecular therapy)

BRAF/MEK Inhibitor Redifferentiation:

Dabrafenib (150 mg BID) + trametinib (2 mg daily) for RAI-refractory BRAF V600E DTC: - Phase II trial (n=24): Restored abnormal I-131 uptake from 5% at baseline to 95% on post-therapy scan - At 6 months: PR 38%, SD 52%, PD 10% - 12-month PFS 82%, 24-month PFS 68% (PMID: 37074727)

Multikinase Inhibitors for RAI-Refractory DTC:

Real-world lenvatinib data: median PFS 36.0 months, OS 76.7 months, ORR 52.3%, DCR 95.5% (PMID: 41565294).

Immunotherapy

• BRAF V600E ATC: Kinase inhibitors + anti-PD-1 achieved mOS not reached for BRAF V600E ATC vs. 4.0 months for non-BRAF (P=0.049); ORR 61.1% (PMID: 39395384)
• Neoadjuvant mutation-based therapy: Converted 9/12 unresectable ATC to resectable (PMID: 40927298)
• PD-L1/PD-1 correlation: BRAF V600E positively correlates with PD-L1 expression, suggesting potential immunotherapy targets (PMID: 29651624)

Active Surveillance (MAXO:0000950)

For low-risk PTMC (Bethesda V–VI, <=1 cm, no adverse features): - Initiated 1993 at Kuma Hospital; zero thyroid-cancer-related deaths reported in 30+ years (PMID: 41196684) - Argentine cohort (n=104): 5- and 10-year cumulative tumor growth 7% and 8%; LN metastasis 0.9% (PMID: 40425952) - 2025 Korean guideline: Recommends AS for adults with confirmed PTMC without adverse features (PMID: 40598902) - HRQOL: No significant difference between AS, ablation, and surgery for uncomplicated PTMC (P=.15) (PMID: 41452620)

Experimental Therapies

• Triple therapy (BRAF + MEK + AKT): Phase I study showed tolerability and objective responses (PMID: 38261444)
• Disulfiram metabolite Cu(DDC)2: Enhances NIS function via proteostasis modulation for RAI therapy (PMID: 41679192)
• Reverse transcriptase inhibitors: Suppress retroelement activity and may restore RAI uptake (PMID: 41296188)
• Patient-derived organoids: Microfluidic DEOs with 76% success rate enable personalized drug screening (PMID: 41761289)

13. Prevention

Primary Prevention

• Radiation protection: Minimize unnecessary radiation exposure; iodine prophylaxis for nuclear emergencies
• Iodine supplementation: Maintain adequate iodine intake to prevent both deficiency and excess-related risk
• Obesity management: Address metabolic risk factors (MAFLD/NAFLD)

Secondary Prevention (Screening and Early Detection)

• Avoiding overdiagnosis: Global thyroid cancer overdiagnosis estimated at ~25%; "incidence has risen exponentially, mostly driven by overdiagnosis of low-risk tumors; however, a small rise in incidence of higher risk tumors has been noted" (PMID: 39087407)
• ACR TI-RADS: Ultrasound-based risk stratification reduces unnecessary biopsies by 19.9–46.5% compared to other systems (PMID: 33112199)
• Molecular testing of indeterminate nodules: BRAF V600E testing on FNA reduces unnecessary surgery

Tertiary Prevention

• Dynamic risk stratification: ATA 2025 response assessment categories (excellent, indeterminate, biochemical incomplete, structural incomplete)
• Active surveillance protocols: Follow-up ultrasound every 6 months for 2 years, then annually (PMID: 40598902)
• TSH suppression: Tailored to risk category
• Genetic counseling: For familial non-medullary thyroid cancer families

14. Other Species / Natural Disease

Comparative Biology

• BRAF ortholog: BRAF is highly conserved across vertebrates
• Mouse (Mus musculus): NCBI Gene ID 109880
• Zebrafish (Danio rerio): NCBI Gene ID 403065

• Dog (Canis lupus familiaris): NCBI Gene ID 475526

• Canine thyroid carcinoma: Dogs develop follicular thyroid carcinoma naturally, though BRAF V600E is not a prominent driver in canine thyroid tumors. Canine thyroid cancer shares some histopathological features with human DTC.

• Evolutionary conservation: The MAPK/ERK signaling pathway is evolutionarily conserved from invertebrates to humans, with BRAF orthologs present in Drosophila (dRaf) and C. elegans (lin-45). Mutations in these orthologs produce developmental phenotypes relevant to understanding BRAF oncogenesis.

Zoonotic Potential

Not applicable — BRAF-mutant PTC is not an infectious or transmissible disease.

15. Model Organisms

Mouse Models

• BrafV600E knock-in mice (thyroid-specific): Thyroid-targeted expression of BrafV600E using Tg-Cre or TPO-Cre drivers produces autochthonous PTC that recapitulates human disease features, including papillary architecture and loss of differentiation markers. scRNA-seq analysis of these models reveals transcriptional heterogeneity and hierarchical trajectories of malignant thyrocytes (PMID: 41935217).
• Beta-catenin attenuation studies: Demonstrated that WNT pathway inhibition can promote differentiation in BRAF-mutant thyroid tumors (PMID: 34224366)
• Limitations: Mouse models may not fully recapitulate human immune microenvironment or dedifferentiation dynamics

Cell Lines

• BCPAP: Human PTC cell line harboring BRAF V600E; widely used for signaling and drug sensitivity studies
• 8505C: ATC cell line with BRAF V600E; used for resistance mechanism studies
• KTC-1: PTC cell line for BRAF inhibitor studies
• Patient-derived organoids (PDOs/DEOs): Microfluidic-generated organoids achieve 92% driver gene concordance, recapitulate immune microenvironment (CD3+/CD56+/CD68+/alpha-SMA+), and enable personalized drug screening (PMID: 41761289)

Zebrafish Models

Zebrafish expressing human BRAF V600E develop thyroid hyperplasia, useful for high-throughput drug screening and studying early oncogenic events.

Key Findings — Statistical Evidence Summary

Finding 1: BRAF V600E Prevalence and Prognostic Impact

BRAF V600E is the most common oncogenic driver in PTC (40–80% prevalence). Meta-analysis of 46 studies (20,570 patients) confirmed significant association with lymph node metastasis (OR=1.38, 95% CI 1.17–1.61) and borderline recurrence risk (OR=1.56, 95% CI 1.00–2.41) (PMID: 41419184). A 2025 study found 78.7% prevalence, with subtype-specific distribution: 88% classic, 38% follicular variant, 100% tall cell (PMID: 40237893).

Finding 2: MAPK Activation and NIS Suppression

BRAF V600E constitutively activates the MAPK pathway and suppresses iodine metabolism genes (PMID: 41368991). NOX4-derived oxidative DNA damage impairs differentiation via epigenetic mechanisms (PMID: 41694580).

Finding 3: BRAF + TERT Synergy

Coexisting mutations independently elevated RAI refractoriness risk (OR=4.8, P=.009) (PMID: 40988283). TERT alone predicts lateral LN metastasis (OR=2.272) (PMID: 40184730).

Finding 4: Redifferentiation Therapy Success

Dabrafenib-trametinib restored RAI uptake from 5% to 95% in BRAF V600E RAI-refractory DTC, with PR in 38% and 24-month PFS of 68% (PMID: 37074727).

Finding 5: Resistance Mechanisms

Three validated mechanisms: TAZ/Hippo (ferroptosis) (PMID: 42035477), FAO-driven epigenetic reprogramming (PMID: 41862440), and RAS feedback activation (PMID: 34072194).

Finding 6: Active Surveillance Safety

Over 30 years of AS data with zero thyroid-cancer-related deaths (PMID: 41196684). MAeSTro study (n=1,177) and multiple international cohorts validate this approach (PMID: 39962344).

Finding 7: Immunotherapy in BRAF-Mutant ATC

Kinase inhibitors + anti-PD-1 achieved ORR 61.1% and mOS not reached in BRAF V600E ATC vs. 4.0 months for non-BRAF (P=0.049) (PMID: 39395384).

Finding 8: Global Overdiagnosis

Estimated at ~25% of thyroid cancers globally, driven by screening intensity in high-SDI regions (PMID: 39389067; PMID: 39330046).

Mechanistic Model: From Mutation to Clinical Phenotype

+----------------------------------------------------------------+
|                    INITIATING EVENT                             |
|         Somatic BRAF V600E mutation (c.1799T>A)                |
|              in thyroid follicular cell                          |
+----------------------------+-----------------------------------+
             |
             v
+----------------------------------------------------------------+
|              CONSTITUTIVE MAPK ACTIVATION                       |
|    BRAF V600E --> MEK1/2 --> ERK1/2 (independent of RAS)       |
+------+----------+----------+----------+----------+-------------+
       |          |          |          |          |
       v          v          v          v          v
  Proliferation  NIS loss   PD-L1 up  TSG silenc  EMT/Invasion
  (Cyclin D1)   (RAI-R)   (immune    (RASSF1A,   (MMP, TGFb)
           evasion)   TIMP3 meth)
       |          |          |          |          |
       +----------+----------+----------+----------+
             |
  +------------------+------------------+
  v                  v                  v
    Low-risk PTC    Intermediate PTC    High-risk PTC
    (indolent)      (moderate risk)     (aggressive)
  |                  |                  |
  |         + TERT mutation              |
  |                  |                  v
  |                  v             Dedifferentiation
  |          RAI-refractory        + TP53 mutation
  |           disease                   |
  |                  |                  v
  |                  |              ATC (lethal)
  v                  v                  v
    Active            BRAF/MEK inhibitor   Immunotherapy +
    surveillance      redifferentiation    targeted therapy
    (safe)            (RAI restored)       (ORR 61%)
+----------------------------------------------------------------+

Evidence Base — Key Literature

Limitations and Knowledge Gaps

1. BRAF V600E prognostic independence: While meta-analyses show significant associations with aggressive features, the independent prognostic value of BRAF V600E after multivariate adjustment remains debated. The borderline recurrence OR (1.56, 95% CI 1.00–2.41) underscores uncertainty (PMID: 41419184).

2. Overdiagnosis confounding: The substantial overdiagnosis of thyroid cancer (~25%) confounds epidemiological analyses and may inflate the apparent indolent behavior of BRAF-mutant PTMC in surveillance studies.

3. Redifferentiation durability: Phase II redifferentiation data (24-month PFS 68%) require longer follow-up and phase III confirmation. Optimal sequencing of redifferentiation vs. MKI therapy is undefined.

4. Resistance mechanisms: While three mechanisms have been identified (TAZ, FAO, RAS feedback), clinical strategies to overcome them remain largely preclinical. The interplay between multiple resistance pathways in individual patients is poorly understood.

5. Pediatric data gaps: Pediatric BRAF-mutant PTC has distinct biology (more aggressive despite excellent survival), but dedicated pediatric clinical trials for targeted therapies are lacking.

6. Single-cell resolution limitations: scRNA-seq studies have revealed immune trajectory and heterogeneity, but spatial transcriptomics data for BRAF-mutant PTC remain limited. Translating single-cell findings to clinical biomarkers requires validation.

7. Geographic and ethnic variation: BRAF V600E prevalence varies widely (40–80%), and GWAS susceptibility loci show population specificity (e.g., NRG1 in Korean, BATF/DHX35 in Italian populations). Cross-ethnic validation of molecular risk models is needed.

8. Active surveillance expansion: MAeSTro-EXP is extending AS to tumors up to 1.5 cm, but long-term outcomes for this expanded cohort are not yet available.

Proposed Follow-up Experiments/Actions

Near-Term (1–2 years)

1. Phase III redifferentiation trial: Prospective randomized trial comparing dabrafenib-trametinib redifferentiation + RAI vs. standard MKI therapy in BRAF V600E RAI-refractory DTC.

2. Combinatorial resistance studies: Clinical trials testing TAZ inhibitors or FAO inhibitors in combination with BRAF/MEK inhibitors in patients progressing on monotherapy.

3. ctDNA monitoring validation: Prospective study validating BRAF V600E ctDNA as a minimal residual disease biomarker after thyroidectomy, with sensitivity analysis against serum thyroglobulin.

4. Expanded active surveillance cohort: Long-term outcomes from MAeSTro-EXP (1.0–1.5 cm tumors) to define safe upper size limit for observation.

Medium-Term (2–5 years)

1. Immunotherapy biomarker discovery: Prospective correlation of PD-L1 expression, BRAF V600E status, and tumor immune microenvironment features with immunotherapy response in advanced DTC/ATC.

2. Multi-ethnic GWAS integration: Pan-ancestry GWAS combining existing data with African, South Asian, and Latin American cohorts to identify universal and population-specific PTC susceptibility loci.

3. Spatial multi-omics of dedifferentiation: Spatial transcriptomics and proteomics profiling of BRAF V600E PTC to PDTC to ATC transition specimens to map the molecular geography of dedifferentiation.

4. Organoid-guided personalized therapy: Clinical trial using patient-derived organoid drug sensitivity testing to guide second-line therapy selection in RAI-refractory DTC.

Long-Term (5+ years)

1. AI-integrated risk stratification: Development and validation of machine learning models integrating ultrasound features, molecular profiling, liquid biopsy, and clinical data for precision risk assessment.

2. Prevention trials: Interventional studies testing whether metabolic syndrome management (weight loss, NAFLD treatment) reduces PTC incidence or modifies BRAF V600E positivity rates.

Ontology Term Summary

Report generated from 5 investigation iterations, 17 confirmed findings, 182 papers reviewed. Last updated: 2026-05-05.